Click to Learn More About AtriCure
AtriClip
LAA Exclusion System, the most widely implanted LAA management
Insist on Eliminating the Source!
Don’t Just Manage the Risk,
device globally (30,000+), specifically indicated for LAA exclusion.
Synergy
for the treatment of Persistent
The first and only device approved
and Longstanding Persistent Afib
Invest in the Global Leader
In Afib Solutions
Join Our
World Class Team

AtriCure: Committed to Atrial Fibrillation Treatment and Solutions

AtriCure is your partner in atrial fibrillation solutions. Our research and rigorous atrial fibrillation clinical trials have led to innovations in ablation technology, including bi-polar and cryoablation, to treat atrial fibrillation with lasting solutions. Our Synergy Ablation System is the first and only device approved by the Food and Drug Administration for the surgical treatment of atrial fibrillation in patients undergoing open heart procedures simultaneously. In addition, we pioneered the AtriClip®, a left atrial appendage occlusion, device that is the most widely implanted for left atrial appendage management worldwide. It is our passion to collaborate with surgeons to make surgeries like the Maze IV simpler to perform and reproducible by more doctors around the world. Through continued commitment to product innovation and education grounded in clinical science, we’re working to reduce the global atrial fibrillation epidemic.

National News

AtriCure to Announce First Quarter 2014 Financial Results

04.04.2014
WEST CHESTER, Ohio--(BUSINESS WIRE)--Apr. 4, 2014-- AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation medical device provider, will release its financial results for the first quarter of 2014 on Thursday, April 24, 2014. AtriCure will host a conference call at 4:30 p.m. Eastern Time on Thursday, April 24, 2014 to discuss its first quarter 2014 financial results. A live webcast of the conference call will be available online from the investor relations page of AtriCure’s corporate website at www.atricure.com. You may also access this call through an operator by calling (866) 271-6130 for domestic callers...

Read More

International News

In the Fight Against Atrial Fibrillation, AtriCure Launches Maze IV Training Program in Europe

10.01.2013
AMSTERDAM, Netherlands--(BUSINESS WIRE)--Oct. 1, 2013-- AtriCure, Inc. (Nasdaq: ATRC), is partnering with leading atrial fibrillation (Afib) centers and thought leaders across Europe to provide best-in-class training on surgical ablation. The launch of an international Maze IV Training program will take place on October 1 in Germany at Sana Stuttgart Cardiac Surgery Center, one of six initial European hospitals selected to participate in this important initiative. This initial course will be led by surgeons recognized as experts in the field of surgical treatment for Afib. They include: James L. Co...

Read More